BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab, a bispecific antibody similar to BioNTech's PM8002. BioNTech's PM8002 antibody is similar to Summit's ...
BioNTech’s oncology strategy centers on a bispecific antibody that the company envisions as the backbone of many potential drug combinations for many types of cancer. Bristol Myer Squibb is buying ...
MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results